An experimental artificial heart includes a self-regulatory control mechanism, or automatic mode, that can be adapted to the changing needs of patients treated for end-stage heart failure. The results of the first series of patients managed with the new cardiac replacement pump in automatic mode are presented in ASAIO Magazine, official journal of the American Society for Artificial Internal Organizations.
The study reports on the response to “pressure sensorself-regulation based on blood flow “in ten patients up to two years after implantation of the artificial artificial heart Carmat (C TAH)”. C TAH automatic mode with built-in pressure sensors effectively produces appropriate physiological responses that reflect patient change. ‘ daily needs and therefore provides an almost physiological cardiac replacement therapy, “according to the new research. The lead author is Ivan Netuka, MD, of the Prague Institute of Clinical and Experimental Medicine.
Automatic mode can increase independence and quality of life in severe heart failure
Cardiac replacement pumps can restore heart flow in patients with end-stage biventricular heart failure (affecting both sides of the heart) the only other option being a heart transplant. However, to allow patients to return home from the hospital and return to their usual activities, the pump should emulate normal heart function, with minimal need for adjustment.
To achieve this goal, the C TAH incorporates an automatic mode that automatically adapts the pumping action of the right and left ventricles in response to the pressure sensors located inside the device, depending on the parameters set by the doctor. The goal is to mimic normal physiological responses to changing needs, especially physical activity.
Dr. Netuka and colleagues analyzed the performance of Auto-Mode in the first ten patients who underwent C TAH in the first European clinical experience. The patients were all men, with a mean age of 60 years. C TAH was used as a bridge to heart transplantation in six patients and as a permanently implanted device in four.
In all patients, the artificial heart was successfully switched from manual control to automatic mode in the operating room. The automatic mode led to “an appropriate immediate cardiac output Hemodynamic data recorded by C TAH showed expected variations in pumping production of the left and right ventricles, in response to changes in pressure and heart rate. normal too.
During nearly five years of aggregate follow-up, medical teams made changes to the automatic mode settings only 20 times. Most adjustments were made during the first 30 days after device placement. Only four were made after the patient went home from the hospital – a rate of about 1 change every 11 months.
“Reducing the need for changes in device management can contribute to greater patient autonomy outside the hospital environment and to improve their quality of life,” write Dr. Netuka and its co-authors. They acknowledge that their study is an initial experience in a relatively small number of patients.
“However,” they add, “it represents a significant leap into the next more physiological stage color replacement therapy. Overall experience of more than four years of device performance represents a positive and promising outcome for patients, while requiring only minimal medical intervention. “Researchers are planning new improvements based on preliminary results; future studies will provide data on exercise response and hospital readmission rates. A clinical trial in the U.S. of C TAH is expected to begin soon.
Ivan Netuka et al, First clinical experience with self-regulation based on blood flow pressure sensor in an artificial heart, ASAIO Magazine (2021). DOI: 10.1097 / MAT.0000000000001485
Wolters Kluwer Health
Citation: New artificial heart shows promising results in “automatic mode”: initial clinical experience (2021, June 18) was reported on June 18, 2021 at https://medicalxpress.com/news/2021-06 -artificial-heart-results-auto -modeinicial-clinical.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.